This trial is investigating the effect of the patient’s own mesenchymal stem cells in multiple sclerosis (MS). The trial is being conducted by the Imperial College Hospital in London expects to enrol 13 patients between January 2013 and July 2015. Bone marrow stem cells will be harvested from all the participants and expanded in the laboratory over 52 days. Participants will be randomly assigned into treatment or control groups. Those in the control group will receive standard treatment and a placebo injection, whilst those in the treatment group will receive their own expanded cells. Neither the patients, nor the doctors will know which group they are in. Participants will be monitored for complications, as well changes in the number of sclerotic lesions in the brain. After 24 weeks patients in the control group will receive their expanded stem cells and both groups monitored again as in the first 24 weeks.